Medical/Pharmaceuticals

Kelun-Biotech to Attend the 44th J.P. Morgan Healthcare Conference, Sharing Its Business Progresses and Innovation Strategies

CHENGDU, China, Jan. 6, 2026 /PRNewswire/ -- The 44th J.P. Morgan Healthcare Conference (JPMHC) will be held inSan Francisco, California, USA, from January 12 to 15, 2026. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) has been invited to attend the ...

2026-01-07 10:44 11090

HealthBiome Achieves Dual Regulatory Milestones: FDA NDI Acknowledgment and Korean MFDS Approval for HB05P Muscle Health Ingredient

Akkermansia muciniphila postbiotic receives both U.S. FDA dietary supplement clearance and Korean functional ingredient approval with muscle health claim, positioning HealthBiome for dual-market launch in 2026 DAEJEON, South Korea, Jan. 6, 2026 /PRNewswire/ -- HealthBiome Inc., a pioneering stri...

2026-01-07 08:00 9156

Celltrion to present at the 44th Annual J.P. Morgan Healthcare Conference

INCHEON, South Korea, Jan. 6, 2026 /PRNewswire/ -- Celltrion, Inc. (068270.KS), a leading global biopharmaceutical company, today announced that Jin-Seok Seo, Chief Executive Officer andHyuk-Jae Lee, Senior Executive Vice President at Celltrion, will present at the 44th Annual J.P. Morgan Healthc...

2026-01-07 07:42 12507

Nuon Medical Unveils Tech-Integrated Packaging Ecosystem at CES 2026, Engineering Clinical Precision into the Point of Skin Contact

LAS VEGAS, Jan. 6, 2026 /PRNewswire/ -- Nuon Medical, a leader in beauty tech innovation, has announced a comprehensive tech-integrated packaging ecosystem at CES 2026. Addressing the global demand for smart s...

2026-01-07 01:00 510

Mind With Heart Robotics Showcases Emotionally Intelligent Robot Lineup at CES 2026, Including CES Innovation Award Honoree An'An Biomimetic Affective AI Panda

Company Expands Therapeutic Robotics Comprehensive Product Lineup Addressing Diverse Emotional and Clinical Support Needs LAS VEGAS, Jan. 6, 2026 /PRNewswire/ -- Mind With Heart Robotics Co., Ltd. showcases its comprehensive lineup of emotionally intelligent robots that mimic natural movements, ...

2026-01-07 01:00 1429

Expanding Healthcare Access for Women's Health -- Noul Unveils AI-Automated Cervical Cancer Diagnostics Solution at CES 2026

* Dramatically cuts diagnostic workflows by 80%…delivering results in under 20 minutes * Decentralized, fully automated diagnostic model helps reduce healthcare infrastructure gaps and supports WHO's 2030 cervical cancer screening goals * Eco-friendly, sustainable AI diagnostics with NGSI so...

2026-01-07 01:00 638

VivaVision Biotech Receives Positive Written Feedback from FDA - VVN461HD New Drug Application (NDA) Requires Only a "Single Phase III" Pivotal Clinical Study in the U.S. for Non-Infectious Anterior Uveitis Treatment

WENZHOU, China, Jan. 6, 2026 /PRNewswire/ -- Recently, VivaVision Biotech (VivaVision), a late clinical-stage, privately-held biotech company focused on developing innovative ophthalmic drugs, announced that it has received the written meeting minutes from the U.S. Food and Drug Administration (F...

2026-01-07 00:00 482

Bambusa Therapeutics Announces First Patient Dosed in Phase Ib Proof-of-Concept COPD Study of BBT002, Reinforcing Bispecific Pipeline Momentum

BOSTON, Jan. 6, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc., a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology & inflammation (I&I), today announceddosing of the first patient in the Phase Ib clinical trial of BBT002, a novel platform-in-a...

2026-01-06 22:30 2118

Terumo Launches SurTract™ Safety Syringe in the United States, Powered by Roncadelle Operations' SafeR® Passive Safety Technology

- New, retractable safety hypodermic line offers enhanced safety, reliability and ease of use while minimizing patient discomfort* - SOMERSET, N.J., Jan. 6, 2026 /PRNewswire/ -- Terumo Medical Corporation, a wholly-owned subsidiary of Terumo Corporation, announced the US launch of its SurTract™ ...

2026-01-06 21:29 5861

Zpeer Launches A-DHA-PT™, a High-Concentration DHA Supplement for Dogs, and Announces Research Collaboration with the University of Tokyo

TOKYO, Jan. 6, 2026 /PRNewswire/ -- Zpeer Inc. (Headquarters: Shibuya, Tokyo; CEO:Toshiya Morino), an animal health company focused on evidence-based therapeutic innovation, has recently announced the launch of A-DHA-PT™ (pronounced "ay-dapt"), a high-concentration DHA supplement designed to supp...

2026-01-06 21:00 422

Xellar and WOOJUNG BIO Announce Multi-Year Strategic Partnership to Advance AI-Enabled Hybrid Human Organ-on-a-Chip (OoC)-Animal Preclinical Platforms

BOSTON and SEOUL, South Korea, Jan. 5, 2026 /PRNewswire/ -- Xellar Biosystems ("Xellar"), a globally leading innovator in next-generation artificial intelligence- and computer vision–assisted, organ-on-a-chip–based drug discovery and development platforms, today announced that it has entered into...

2026-01-06 08:00 8914

Nanjing Delova Announces Statistically Significant and Clinically Meaningful Results From Two Phase 3 Trials of QP-6211 for the Treatment of Postoperative Pain

* Treatment with QP-6211 achieved primary and all key secondary endpoints in both placebo- and active-controlled Phase 3 trials following hemorrhoidectomy or bunionectomy. * QP-6211 demonstrated statistically significant reductions in postoperative pain and opioid consumption through 72 hou...

2026-01-05 23:00 8860

Flat Medical Appoints Eric Steen, Former B. Braun Executive, as Strategic Advisor

Medical Device Industry Veteran to Guide Capital Strategy and Market Expansion AUSTIN, Texas and TAIPEI, Jan. 5, 2026 /PRNewswire/ -- Flat Medical, a leader in precision safety technology for clinical procedures, today announced the appointment ofEric Steen as Strategic Advisor. Mr. Steen brings ...

2026-01-05 21:30 9110

SynuSight Biotech, ABLi Therapeutics and XingImaging Announce Strategic Collaboration to Implement Alpha-Synuclein PET Imaging into Clinical Trials Evaluating Risvodetinib as a Disease-modifying Therapy for Parkinson's disease

SynuSight Biotech has licensed 18F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment SHANGHAI, ATLANTA and NEW HAVEN, Conn. , Jan. 5, 2026 /PRNewswire/ -- SynuSight Biotech ("SynuSight"), a biotechnology company...

2026-01-05 21:05 5625

Earendil Labs Announces Strategic Collaboration with Sanofi to Discover Bispecific Antibodies for Autoimmune Diseases

WILMINGTON, Del., Jan. 5, 2026 /PRNewswire/ -- Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, today announced a strategic collaboration with Sanofi to apply Earendil's discovery platform to multiple autoimmune and inflammatory disea...

2026-01-05 18:00 7868

Hyphens Pharma out‑licences Cerapro® MED Skin Barrier Cream for six European countries

* Cerapro® is a patented, skin pH-lowering cream approved for the treatment of atopic dermatitis under the EuropeanMedical Device Regulation (CE Mark) * Product launch targeted for 2026 in six European markets, including Switzerland, Austria, the Netherlands and Belgium.  SINGAPORE, Jan. 5, 20...

2026-01-05 17:30 9508

ScinoPharm Secures U.S. FDA Approval for Glatiramer Acetate Injection for the Treatment of Multiple Sclerosis

TAINAN, Jan. 5, 2026 /PRNewswire/ -- ScinoPharm Taiwan (TWSE: 1789) today announced a landmark achievement in the global pharmaceutical landscape, securing U.S. Food and Drug Administration (FDA) approval for Glatiramer Acetate Injection, a treatment for Multiple Sclerosis (MS), making it the onl...

2026-01-05 14:00 8916

WuXi Biologics Achieves ISO 20400 Certification, Setting Benchmark in Sustainable Procurement

WUXI, China, Jan. 4, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK) announced it has achieved ISO 20400 Sustainable Procurement certification, an internationally recognized standard that integrates sustainability principles into procurement practices and promotes transparency and responsibility ac...

2026-01-05 11:57 7531

Insilico Medicine Announce US$888 Million Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology

* Insilico Medicine achieved an R&D collaboration with Servier valued at up to US$888 million, focused on discovering and developing innovative oncology therapies, by combining Insilico's AI-driven drug discovery platforms with Servier's global expertise in cancer drug development.  * Under t...

2026-01-05 08:30 7694

EXOSYSTEMS' exoRehab Named a CES Innovation Awards 2026 Honoree in Digital Health

AI-powered wearable brings clinic-grade muscle tracking to at-home rehab. Live demos Jan. 6–9 at CES 2026. SEOUL, South Korea, Jan. 3, 2026 /PRNewswire/ -- EXOSYSTEMS Inc. announced that exoRehab, its Remote Therapeutic Monitoring (RTM) solution for musculoskeletal care, has been selected as a C...

2026-01-03 23:27 5805
1 ... 26272829303132 ... 260